Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK |
Therapy | Alectinib + Zoledronic acid |
Indication/Tumor Type | large cell neuroendocrine carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK | large cell neuroendocrine carcinoma | predicted - sensitive | Alectinib + Zoledronic acid | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Alecensa (alectinib) and Zoledronic acid resulted in a partial response with progression-free survival ongoing at 21 months in a patient with metastatic large cell neuroendocrine carcinoma harboring EML4-ALK (e6:e20) (PMID: 38023218). | 38023218 |
PubMed Id | Reference Title | Details |
---|---|---|
(38023218) | Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review. | Full reference... |